BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18051426)

  • 1. [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase].
    Tanaka A
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1786-7. PubMed ID: 18051426
    [No Abstract]   [Full Text] [Related]  

  • 2. A Plasmodium falciparum FK506-binding protein (FKBP) with peptidyl-prolyl cis-trans isomerase and chaperone activities.
    Monaghan P; Bell A
    Mol Biochem Parasitol; 2005 Feb; 139(2):185-95. PubMed ID: 15664653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporins: lack of correlation between antischistosomal properties and inhibition of cyclophilin isomerase activity.
    Khattab A; Pica-Mattoccia L; Klinkert MQ; Wenger R; Cioli D
    Exp Parasitol; 1998 Sep; 90(1):103-9. PubMed ID: 9709036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptidyl-prolyl isomerase inhibitors.
    Wang XJ; Etzkorn FA
    Biopolymers; 2006; 84(2):125-46. PubMed ID: 16302169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraligand hydrophobic interactions rationalize drug affinities for peptidyl-prolyl cis-trans isomerase protein.
    Bizzarri M; Marsili S; Procacci P
    J Phys Chem B; 2011 May; 115(19):6193-201. PubMed ID: 21500789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective elution of target protein from affinity resins by a simple reductant with a thiol group.
    Mabuchi M; Haramura M; Shimizu T; Nishizaki T; Tanaka A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7361-4. PubMed ID: 21067925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolating the whole complex of target proteins of FK506 using affinity resins from novel solid phases.
    Takahashi T; Shiyama T; Mori T; Hosoya K; Tanaka A
    Anal Bioanal Chem; 2006 May; 385(1):122-7. PubMed ID: 16601955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering of monomeric FK506-binding protein 22 with peptidyl prolyl cis-trans isomerase. Importance of a V-shaped dimeric structure for binding to protein substrate.
    Budiman C; Bando K; Angkawidjaja C; Koga Y; Takano K; Kanaya S
    FEBS J; 2009 Aug; 276(15):4091-101. PubMed ID: 19558490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations.
    Lamb ML; Jorgensen WL
    J Med Chem; 1998 Oct; 41(21):3928-39. PubMed ID: 9767630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
    Stebbins JL; Zhang Z; Chen J; Wu B; Emdadi A; Williams ME; Cashman J; Pellecchia M
    J Med Chem; 2007 Dec; 50(26):6607-17. PubMed ID: 18038971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of gene regulation centered on peptidyl prolyl cis-trans isomerase].
    Horikoshi M; Himukai R; Kuzuhara T
    Tanpakushitsu Kakusan Koso; 2004 Jun; 49(8):1195-203. PubMed ID: 15209215
    [No Abstract]   [Full Text] [Related]  

  • 12. A versatile method of identifying specific binding proteins on affinity resins.
    Yamamoto K; Yamazaki A; Takeuchi M; Tanaka A
    Anal Biochem; 2006 May; 352(1):15-23. PubMed ID: 16540075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting prolyl isomerase activity by hybrid organic-inorganic molecules containing rhodium(II) fragments.
    Coughlin JM; Kundu R; Cooper JC; Ball ZT
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5203-6. PubMed ID: 25442313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimalarial effects of macrolactones related to FK520 (ascomycin) are independent of the immunosuppressive properties of the compounds.
    Monaghan P; Fardis M; Revill WP; Bell A
    J Infect Dis; 2005 Apr; 191(8):1342-9. PubMed ID: 15776382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential responses of the backbone and side-chain conformational dynamics in FKBP12 upon binding the transition-state analog FK506: implications for transition-state stabilization and target protein recognition.
    Brath U; Akke M
    J Mol Biol; 2009 Mar; 387(1):233-44. PubMed ID: 19361439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FKBP ligands as novel therapeutics for neurological disorders.
    Christner C; Herdegen T; Fischer G
    Mini Rev Med Chem; 2001 Nov; 1(4):377-97. PubMed ID: 12369964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptidyl-prolyl isomerase activity in chloroplast thylakoid lumen is a dispensable function of immunophilins in Arabidopsis thaliana.
    Ingelsson B; Shapiguzov A; Kieselbach T; Vener AV
    Plant Cell Physiol; 2009 Oct; 50(10):1801-14. PubMed ID: 19717822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotrophic effects of FK506 in dogs.
    Starzl TE; Porter KA; Mazzaferro V; Todo S; Fung J; Francavilla A
    Transplantation; 1991 Jan; 51(1):67-70. PubMed ID: 1702912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FKBP family proteins: immunophilins with versatile biological functions.
    Kang CB; Hong Y; Dhe-Paganon S; Yoon HS
    Neurosignals; 2008; 16(4):318-25. PubMed ID: 18635947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between structure and function of peptidyl-prolyl isomerase].
    Ikura T; Kinoshita K; Ito N
    Tanpakushitsu Kakusan Koso; 2009 Feb; 54(2):167-72. PubMed ID: 19205352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.